StockData

Orchestra BioMed Holdings, Inc. (OBIO) stock

OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$7.46+0.49 (+7.03%)

Close on Nov 18, 2026Market cap $448.38MP/E –Yield –

Orchestra BioMed operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Orchestra BioMed's operating income for the twelve months ending Jun 30, 2026 was -$57.99M. For fiscal 2025 it was -$51.81M. The highest annual figure on record is -$394.76K in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.81M–
FY2024Dec 31, 2024-$64.30M–
FY2023Dec 31, 2023-$51.51M–
FY2022Dec 31, 2022-$32.66M–
FY2021Dec 31, 2021-$394.76K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.36M–
Q1 FY2026Mar 31, 2026-$22.08M–
Q4 FY2025Dec 31, 2025$6.75M–
Q3 FY2025Sep 30, 2025-$20.31M–
Q2 FY2025Jun 30, 2025-$19.33M–
Q1 FY2025Mar 31, 2025-$18.92M–
Q4 FY2024Dec 31, 2024-$16.68M–
Q3 FY2024Sep 30, 2024-$16.34M–
Q2 FY2024Jun 30, 2024-$16.86M–
Q1 FY2024Mar 31, 2024-$14.42M–
Q4 FY2023Dec 31, 2023-$12.48M–
Q3 FY2023Sep 30, 2023-$14.52M–
Q2 FY2023Jun 30, 2023-$12.96M–
Q1 FY2023Mar 31, 2023-$11.55M–
Q4 FY2022Dec 31, 2022-$9.83M–
Q3 FY2022Sep 30, 2022-$10.07M–
Q2 FY2022Jun 30, 2022-$7.63M–
Q1 FY2022Mar 31, 2022-$5.13M–
Q4 FY2021Dec 31, 2021-$92.05K–
Q3 FY2021Sep 30, 2021-$94.45K–
Q2 FY2021Jun 30, 2021-$96.32K–
Q1 FY2021Mar 31, 2021-$111.95K–
Q3 FY2020Sep 30, 2020-$68.63K–

More Orchestra BioMed figures

See a number that looks wrong?